Skip to main content

Table 6 Scenario-analyses*: discounted and undiscounted incremental lifetime cost- effectiveness ratios

From: Cost-effectiveness of enzyme replacement therapy for Fabry disease

 

ICER based on years free of end-organ damage, in €

ICER based QALYs, in €

 

Discounted

Undiscounted

Discounted

Undiscounted

Base case typical patient

3,318,239

6,560,885

3,282,252

6,065,529

1. start ERT at 40 years

3,662,891

12,996,662

2,158,245

7,637,076

2. lower QoL during the natural course

-

-

509,719

1,226,674

3. course of disease in patients with the classical phenotype only

3,274,869

6,280,356

3,015,385

5,575,064

4. ACE-ARB during natural course

293,213,929

566,675,324

11,559,105

21,223,686

5. No ERT in case of 2 complications

3,307,363

6,529,644

3,271,494

6,036,644

6. including indirect costs of production loss

3,320,374

6,568,971

3,284,265

6,073,006

  1. * Given a 1:1 male to female ratio.